Helpline
Call 1.855.378.4373 to schedule a call time with a specialist or visit scheduler.drugfree.org
Helpline
Helpline
Call 1.855.378.4373 to schedule a call time with a specialist

The Latest News from Our Field

We curate a digest of the latest news in our field for advocates, policymakers, community coalitions and all who work toward shaping policies and practices to effectively prevent substance use and treat addiction.

The White House on Wednesday designated fentanyl mixed with the animal tranquilizer xylazine to be an emerging threat to the United States, CNN reports.
Real estate developers are working with health care providers and state and local governments to open more addiction recovery centers, psychiatric facilities and other behavioral health clinics to meet growing demand, The New York Times reports.
A Drug Enforcement Administration proposal that would limit telehealth prescriptions for buprenorphine to an initial 30-day supply until the patient can be seen in person by a physician is raising concerns among addiction medicine advocates, Roll Call reports.
Find more of our must-reads in policy news, including the ONDCP declaring fentanyl combined with xylazine an emerging threat.
View our curated digest of the latest research news, including a study on the association between hospitals adopting an emergency department buprenorphine treatment pathway and patients' subsequent initiation of buprenorphine treatment.
A new study finds the expanded availability of opioid use disorder-related telehealth services and medications during the pandemic were associated with a lower risk of fatal overdoses among Medicare patients.
Scientists evaluating more than 100 studies of alcohol consumption conclude that there are no significant health benefits to drinking moderately, ABC News reports.
More than $50 billion in settlement money is being delivered from opioid corporations to states and localities, yet only 12 states have committed to detailed public reporting on where their opioid settlement funding is going, Kaiser Health News reports.
Find more of our must-reads in policy news, including a federal judge striking down the ACA preventive services mandate.
View our curated digest of the latest research news, including a scoping review of implementation considerations for harm reduction vending machines.
The U.S. Food and Drug Administration on Wednesday approved the first over-the-counter naloxone nasal spray, The New York Times reports.
Test strips will soon be available to detect the presence of the animal sedative xylazine, also known as tranq, in illicit substances, STAT reports.
People who survive an opioid overdose have a lower risk of dying from a subsequent overdose if they are treated with the opioid addiction medication buprenorphine, a new study suggests.
Find more of our must-reads in policy news, including the FDA approving Narcan naloxone nasal spray for over-the-counter, nonprescription use.
View our curated digest of the latest research news, including a study on the ecological momentary assessment of heavy episodic drinking in the early postpartum period by Sarah Dauber, Vice President of Research and Evaluation at the Partnership to End Addiction.
The U.S. Drug Enforcement Administration this week issued a warning about the widespread threat of fentanyl mixed with the veterinary tranquilizer xylazine, CNN reports.
State legislators around the country are seeking harsher penalties for possessing fentanyl and other synthetic opioids, despite evidence showing harm reduction and treatment are needed more, AP reports.
California Governor Gavin Newsom is calling for a measure on the 2024 ballot that would fund a major expansion of housing and treatment for residents experiencing mental illness and substance use disorders, AP reports.
Find more of our must-reads in policy news, including the reintroduction of the Family Support Services for Addiction Act.
View our curated digest of the latest research news, including a case report on the association between delta-8 THC and psychosis.
Some pharmacies in northern Mexico that cater to U.S. tourists are selling medications that are laced with fentanyl and methamphetamine, according to a new study.
The $21 billion opioid settlement brokered last year between the three largest U.S. pharmaceutical distributors and the attorneys general of 46 states has made it more difficult for some patients to obtain other types of medications, including those for addiction, anxiety and attention deficit hyperactivity disorder, according to The New York Times.
The Department of Justice this week announced a suit against Rite Aid, alleging the pharmacy chain knowingly filled unlawful prescriptions for controlled substances, including opioids.
Find more of our must-reads in policy news, including distributor requirements from the opioid settlement that are hindering access to medications.
View our curated digest of the latest research news, including a survey on pod-based e-cigarette use among U.S. college-aged adults.
1 9 10 11 12 13 359